Keros Therapeutics, Inc. (KROS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.830.00%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KROS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.2% |
| Our one-year growth estimate | diamond | -52.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 2.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
KROS — earnings miss
Dated 2026-08-03
Results of Operations and Financial Condition. On August 3, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Why it matters: Cash fell from $287.4 million at year-end 2025 to $257.6 million at June 2026. Management said cash could fund costs into the first half of 2028.
Worry ifThe November 4 update keeps the cash runway into the first half of 2028 and reports cash near or above $257.6 million.
Less concerning ifThe update moves the cash runway earlier than the first half of 2028 or reports cash below $257.6 million.
Why it matters: The data will test whether the early muscle and bone changes also help people with DMD.
Watch forInitial Phase 2 data arrive in the first half of 2027 and show a clear benefit on a trial measure.
Also watch forThe data show no clear benefit on a trial measure, or the readout slips past the first half of 2027.
Why it matters: Takeda's trial progress may lead to more milestone payments for Keros. A delay would weaken that path.
Watch forTakeda says ELRiSE MF is enrolling patients and giving them doses. No pause or delay has been announced.
Also watch forTakeda reports a trial pause, a major delay, or ends ELRiSE MF.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$167 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $455 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,462 loss on $10,000 · 54.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.